IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by National Bank of Canada FI

National Bank of Canada FI trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 37.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,520 shares of the company’s stock after selling 24,647 shares during the quarter. National Bank of Canada FI owned 0.05% of IDEXX Laboratories worth $21,168,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in IDXX. Wellington Management Group LLP grew its holdings in shares of IDEXX Laboratories by 2.0% in the third quarter. Wellington Management Group LLP now owns 3,486 shares of the company’s stock valued at $1,524,000 after purchasing an additional 67 shares in the last quarter. CX Institutional acquired a new position in IDEXX Laboratories in the fourth quarter valued at $228,000. Mutual Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $260,000. CVA Family Office LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $108,000. Finally, Assenagon Asset Management S.A. grew its stake in IDEXX Laboratories by 25.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after buying an additional 8,831 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Barclays lowered their price target on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Finally, William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $585.89.

IDEXX Laboratories Trading Up 0.9 %

Shares of IDXX stock traded up $4.05 during mid-day trading on Thursday, hitting $475.39. 280,556 shares of the company’s stock were exchanged, compared to its average volume of 474,136. The stock has a market cap of $39.26 billion, a price-to-earnings ratio of 45.63, a PEG ratio of 3.85 and a beta of 1.32. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The stock has a 50-day simple moving average of $496.49 and a two-hundred day simple moving average of $518.26.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. Equities analysts expect that IDEXX Laboratories, Inc. will post 11 EPS for the current fiscal year.

Insider Activity

In related news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the transaction, the director now owns 161 shares in the company, valued at $87,068.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.